Consolidation is happening presently, SP has a median value of .86$ per share, key support @ .76, support @ .79, Resistance @ .86$; days high @ .90 ps. Average guidance is bullish with .86$ per share daily target. Renewed gains for the short term evident from short term higher highs and highers lows with key supports. Volume increasing. New short term highs indicate resistance is fragile to .94$ ps with increasing volume. Share price target by Oct 17th/18 range bound 1.05$ - 2.05$ per share. Lower range is indicative of projected figures (52 - point); Upper range is indicative of announcements (Not including stage 3 trial data). Unable to determine effects of Stage 3 clinical data on analysis for the long term. Analyst price target 2.30$ per share. Writers Price target: new 52 weeks highs prior to year end. In short, the value of Tetra bio-pharma at present does not reflect the valuation of the company with successful stage 3 trials as it will have a substantial effect on the share price. Successful preliminary data on stage 3 trials for PPP001 will guarantee success for PPP002 and PPP005 as the same chemical makeup is used. The SP for Tetra Bio Pharma with preliminary data on Stage 3 trials will likely add $300 million on top of the current market cap of 125$ million. Subsequently, the company will likely reach a half billion$ evaluation on those results prior to November, 2018.
Genacol partnership will begin to add value for Tetra Bio Pharma shareholders in the near term. - Projected 0.00 EPS Q1, 2019; 0.02 Q2 2019; .05$ EPS Q3 2019. Upcoming Catalyst: North Bud IPO; Stage 3 preliminary Data; Additional Analyst coverage; Gov't FDA announcements; Additions to the board. Fair Price for Tetra Bio-Pharma currently stands @ 1.24$ per share.
TETRA BIO PHARMA INC – SIGNING OF A DEFINITIVE DISTRIBUTION AGREEMENT WITH KAMADA IS EXPECTED TO FOLLOW SHORTLY; 23/04/2018 – Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitry; 15/05/2018 – KAMADA LTD KMDA.TA SEES FY 2018 REVENUE $116 MLN TO $120 MLN; 15/05/2018 – KAMADA LTD – REAFFIRMING GUIDANCE OF $116 MLN TO $120 MLN IN TOTAL REVENUES FOR 2018; 24/04/2018 – TETRA BIO PHARMA-WILL BE ELIGIBLE TO RECEIVE CERTAIN MILESTONE PAYMENTS & AN UNDISCLOSED PERCENTAGE OF SALES OF PPP001 GENERATED BY KAMADA IN ISRAEL
Insider Reports: North Bud IPO listing is coming very very soon, New BNN interview scheduled before months end.
isnarain
⋅
Rumor on the street that Tetra Bio Pharma is working on Signing a deal with Shoppers Drug Market on further supplying OTC Products. As no letter of intent has been signed, I would take this as a grain of salt.
isnarain
⋅
Yes, I am currently picking up shares at .81$. Asked if i owned any shares of TBP. As of present, I am accumulating.
AAAAAVVVVV
⋅
@isnarain, I sold my 40k shares @ 0.9 from an average of 0.63. I think it will dip a little bit more, 'cuz of the carnage in the cannabis sector :) anyways I'm super positive about the future
isnarain
⋅
@THC400, Tetra is in a place where any institutional investment will drive the sp through the roof. I believe this will happen less 3 months. The 60's are a thing of the past. The 70's will be short lived. Any additional investment from Aphria or pharma (partners) will do wonders. I've been following Tetra for sometime and now is the time to buy as stage 3 preliminary data will likely be released prior Oct 17th. I'm quite certain the share price will surge beyond 2$ per share by Oct 17th.
TETRA BIO PHARMA INC – SIGNING OF A DEFINITIVE DISTRIBUTION AGREEMENT WITH KAMADA IS EXPECTED TO FOLLOW SHORTLY; 23/04/2018 – Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitry; 15/05/2018 – KAMADA LTD KMDA.TA SEES FY 2018 REVENUE $116 MLN TO $120 MLN; 15/05/2018 – KAMADA LTD – REAFFIRMING GUIDANCE OF $116 MLN TO $120 MLN IN TOTAL REVENUES FOR 2018; 24/04/2018 – TETRA BIO PHARMA-WILL BE ELIGIBLE TO RECEIVE CERTAIN MILESTONE PAYMENTS & AN UNDISCLOSED PERCENTAGE OF SALES OF PPP001 GENERATED BY KAMADA IN ISRAEL